Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...

Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub. The first application ...

About a week after the FDA convened its latest meeting to discuss strategies for reducing racial biases in widely available pulse oximetry technology, Masimo has released new study data suggesting ...

Masimo Corp.’s pulse oximetry technology avoids the dangerous under-recognition of low oxygen levels in people of color that plagues many pulse oximeters on the market, a peer-reviewed study in the ...

Eliminating racial bias in pulse oximetry has been top of mind lately for many devicemakers and healthcare providers, as well as the FDA, which convened an advisory committee meeting earlier this ...

Across the healthcare landscape, more and more conversations are focusing on health inequity. Specific to pulse oximetry, recent research, media, and regulatory discussions have been raising awareness ...

Irvine, California-based Masimo Technologies, which makes non-invasive patient monitoring devices and sensors, has received FDA 510(k) clearance for its forehead sensor. The adhesive TFA-1 Forehead ...

Masimo Corp. received a pinch of good news with the U.S. FDA’s clearance of its medical-grade fingertip pulse oximeter, Mightysat Medical, for over-the-counter (OTC) sale. The device uses the same ...

Masimo Corp. in Irvine now sells its MightySat pulse oximeter in about 100 Apple stores and on Apple.com. It previously had been available only online at a roster of websites that include Amazon.com ...

Masimo has raised the stakes in its escalating pulse oximetry-focused feud with competitor Covidien. And the game is beginning to get interesting. As part of a campaign to "help clinicians separate ...